|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Baldwin LA, Huang B, Miller RW, Tucker T,
Goodrich ST, Podzielinski I, DeSimone CP, Ueland FR, van Nagell JR
and Seamon LG: Ten-year relative survival for epithelial ovarian
cancer. Obstet Gynecol. 120:612–618. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Damia G and Sessa C: Successes and
limitations of targeted cancer therapy in ovarian cancer. Prog
Tumor Res. 41:89–97. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hu S, Balakrishnan A, Bok RA, Anderton B,
Larson PE, Nelson SJ, Kurhanewicz J, Vigneron DB and Goga A:
13C-pyruvate imaging reveals alterations in glycolysis that precede
c-MYC induced tumor formation and regression. Cell Metab.
14:131–142. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jiang SH, Li J, Dong FY, Yang JY, Liu DJ,
Yang XM, Wang YH, Yang MW, Fu XL, Zhang XX, et al: Increased
serotonin signaling contributes to the Warburg effect in pancreatic
tumor cells under metabolic stress and promotes growth of
pancreatic tumors in mice. Gastroenterology. 153:277–291.e19. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chang CC, Zhang C, Zhang Q, Sahin O, Wang
H, Xu J, Xiao Y, Zhang J, Rehman SK, Li P, et al: Upregulation of
lactate dehydrogenase a by 14-3-3ζ leads to increased glycolysis
critical for breast cancer initiation and progression. Oncotarget.
7:35270–35283. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Slupsky CM, Steed H, Wells TH, Dabbs K,
Schepansky A, Capstick V, Faught W and Sawyer MB: Urine metabolite
analysis offers potential early diagnosis of ovarian and breast
cancers. Clin Cancer Res. 16:5835–5841. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Anderson AS, Roberts PC, Frisard MI,
McMillan RP, Brown TJ, Lawless MH, Hulver MW and Schmelz EM:
Metabolic changes during ovarian cancer progression as targets for
sphingosine treatment. Exp Cell Res. 19:1431–1442. 2013. View Article : Google Scholar
|
|
10
|
Sun L, Yin Y, Clark LH, Sun W, Sullivan
SA, Tran AQ, Han J, Zhang L, Guo H, Madugu E, et al: Dual
inhibition of glycolysis and glutaminolysis as a therapeutic
strategy in the treatment of ovarian cancer. Oncotarget.
8:63551–63561. 2017.PubMed/NCBI
|
|
11
|
Watanabe N, Komatsu S, Ichikawa D, Miyamae
M, Ohashi T, Okajima W, Kosuga T, Konishi H, Shiozaki A, Fujiwara
H, et al: Overexpression of YWHAZ as an independent prognostic
factor in adenocarcinoma of the esophago-gastric junction. Am J
Cancer Res. 6:2729–2736. 2016.PubMed/NCBI
|
|
12
|
Neal CL, Yao J, Yang W, Zhou X, Nguyen NT,
Lu J, Danes CG, Guo H, Lan KH, Ensor J, et al: 14-3-3zeta
overexpression defines high risk for breast cancer recurrence and
promotes cancer cell survival. Cancer Res. 69:3425–3432. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lin M, Morrison CD, Jones S, Mohamed N,
Bacher J and Plass C: Copy number gain and oncogenic activity of
YWHAZ/14-3-3zeta in head and neck squamous cell carcinoma. Int J
Cancer. 125:603–611. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tang Y, Liu S, Li N, Guo W, Shi J, Yu H,
Zhang L, Wang K, Liu S and Cheng S: 14-3-3ζ promotes hepatocellular
carcinoma venous metastasis by modulating hypoxia-inducible
factor-1α. Oncotarget. 7:15854–15867. 2016.PubMed/NCBI
|
|
15
|
Lu J, Guo H, Treekitkarnmongkol W, Li P,
Zhang J, Shi B, Ling C, Zhou X, Chen T, Chiao PJ, et al: 14-3-3zeta
cooperates with ErbB2 to promote ductal carcinoma in situ
progression to invasive breast cancer by inducing
epithelial-mesenchymal transition. Cancer Cell. 16:195–207. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bergamaschi A, Frasor J, Borgen K,
Stanculescu A, Johnson P, Rowland K, Wiley EL and Katzenellenbogen
BS: 14-3-3ζ as a predictor of early time to recurrence and distant
metastasis in hormone receptor-positive and -negative breast
cancers. Breast Cancer Res Treat. 137:689–696. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pozuelo Rubio M, Peggie M, Wong BH,
Morrice N and MacKintosh C: 14-3-3s regulate
fructose-2,6-bisphosphate levels by binding to PKB-phosphorylated
cardiac fructose-2,6-bisphosphate kinase/phosphatase. EMBO J.
2:3514–3523. 2003. View Article : Google Scholar
|
|
18
|
Lim GE, Piske M and Johnson JD: 14-3-3
proteins are essential signaling hubs for beta cell survival.
Diabetologia. 56:825–837. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kim CY, Jeong SY, Chong GO, Son SH, Jung
JH, Kim DH, Lee SW, Ahn BC and Lee J: Quantitative metabolic
parameters measured on F-18 FDG PET/CT predict survival after
relapse in patients with relapsed epithelial ovarian cancer.
Gynecol Oncol. 136:498–504. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yang XM, Cao XY, He P, Li J, Feng MX,
Zhang YL, Zhang XL, Wang YH, Yang Q, Zhu L, et al: Overexpression
of Rac GTPase activating protein 1 contributes to proliferation of
cancer cells by reducing hippo signaling to promote cytokinesis.
Gastroenterology. 155:1233–1249.e22. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Powell DW, Rane MJ, Chen Q, Singh S and
McLeish KR: Identification of 14-3-3zeta as a protein kinase B/Akt
substrate. J Biol Chem. 277:21639–21642. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yeung TL, Leung CS, Yip KP, Au Yeung CL,
Wong ST and Mok SC: Cellular and molecular processes in ovarian
cancer metastasis. A review in the theme: Cell and molecular
processes in cancer metastasis. Am J Physiol Cell Physiol.
309:C444–C456. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Vaughan S, Coward JI, Bast RC Jr, Berchuck
A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R,
Etemadmoghadam D, et al: Rethinking ovarian cancer: Recommendations
for improving outcomes. Nat Rev Cancer. 11:719–725. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Murata T, Takayama K, Urano T, Fujimura T,
Ashikari D, Obinata D, Horie-Inoue K, Takahashi S, Ouchi Y, Homma Y
and Inoue S: 14-3-3ζ, a novel androgen-responsive gene, is
upregulated in prostate cancer and promotes prostate cancer cell
proliferation and survival. Clin Cancer Res. 18:5617–5627. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
He Y, Wu X, Liu X, Yan G and Xu C:
LC-MS/MS analysis of ovarian cancer metastasis-related proteins
using a nude mouse model: 14-3-3 zeta as a candidate biomarker. J
Proteome Res. 9:6180–6190. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Su R, Gong JN, Chen MT, Song L, Shen C,
Zhang XH, Yin XL, Ning HM, Liu B, Wang F, et al: c-Myc suppresses
miR-451_ǀYWTAZ/AKT axis via recruiting HDAC3 in acute myeloid
leukemia. Oncotarget. 7:77430–77443. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Weerasekara VK, Panek DJ, Broadbent DG,
Mortenson JB, Mathis AD, Logan GN, Prince JT, Thomson DM, Thompson
JW and Andersen JL: Metabolic-stress-induced rearrangement of the
14-3-3ζ interactome promotes autophagy via a ULK1- and
AMPK-regulated 14-3-3ζ interaction with phosphorylated Atg9. Mol
Cell Biol. 34:4379–4388. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Goc A, Abdalla M, Al-Azayzih A and
Somanath PR: Rac1 activation driven by 14-3-3ζ dimerization
promotes prostate cancer cell-matrix interactions, motility and
transendothelial migration. PLoS One. 7:e405942012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Choi JE, Hur W, Jung CK, Piao LS, Lyoo K,
Hong SW, Kim SW, Yoon HY and Yoon SK: Silencing of 14-3-3ζ
over-expression in hepatocellular carcinoma inhibits tumor growth
and enhances chemosensitivity to cis-diammined dichloridoplatium.
Cancer Lett. 303:99–107. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Anderson AS, Roberts PC, Frisard MI,
Hulver MW and Schmelz EM: Ovarian tumor-initiating cells display a
flexible metabolism. Exp Cell Res. 328:44–57. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lim GE, Piske M, Lulo JE, Ramshaw HS,
Lopez AF and Johnson JD: Ywhaz/14-3-3ζ deletion improves glucose
tolerance through a GLP-1-dependent mechanism. Endocrinology.
157:2649–2659. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Taylor C, Mannion D, Miranda F,
Karaminejadranjbar M, Herrero-Gonzalez S, Hellner K, Zheng Y,
Bartholomeusz G, Bast RC Jr and Ahmed AA: Loss of PFKFB4 induces
cell death in mitotically arrested ovarian cancer cells.
Oncotarget. 8:17960–17980. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Danes CG, Wyszomierski SL, Lu J, Neal CL,
Yang W and Yu D: 14-3-3 zeta down-regulates p53 in mammary
epithelial cells and confers luminal filling. Cancer Res.
68:1760–1767. 2008. View Article : Google Scholar : PubMed/NCBI
|
